Related by context. All words. (Click for frequent words.) 73 untreated metastatic colorectal 73 leukemia CLL 68 leukemia AML 67 untreated metastatic pancreatic 66 untreated multiple myeloma 66 dacarbazine DTIC 65 untreated AML 65 leukemia ALL 65 recurrent glioblastoma multiforme 64 Uricase PEG 64 pegylated liposomal doxorubicin 64 Fludarabine 64 relapsed leukemia 64 adriamycin 64 gefitinib Iressa 64 untreated de novo 63 erlotinib Tarceva ® 63 lenalidomide Revlimid R 63 demonstrated antitumor activity 63 Myelodysplastic Syndrome MDS 63 metastatic gastric 62 anthracycline taxane 62 metastatic castration resistant 62 metastatic lung cancer 62 mRCC 62 Rituxan rituximab 62 imatinib Gleevec ® 62 docetaxel chemotherapy 61 docetaxel Taxotere 61 Ribavirin causes 61 refractory AML 61 cetuximab Erbitux R 61 refractory acute myeloid 61 mutated KRAS gene 61 HBeAg negative 61 non splenectomized 61 trastuzumab Herceptin R 61 taxane chemotherapy 61 metastatic malignant 61 tumors GIST 61 relapsed MM 61 thalidomide Thalomid 61 idiopathic thrombocytopenic purpura ITP 61 sorafenib Nexavar 61 cancer mCRC 61 Gleevec resistant 61 dasatinib Sprycel ® 61 metastatic hormone refractory 61 trastuzumab Herceptin ® 60 BARACLUDE ® 60 achieved ACR# 60 HBeAg positive patients 60 TNF antagonist 60 Telintra 60 pediatric acute lymphoblastic 60 Doxil ® 60 Velcade bortezomib 60 Flu Cy 60 stage IIIB 60 non metastatic osteosarcoma 60 metastatic kidney 60 alkylating agent 60 interferon therapy 60 imatinib Gleevec 60 heavily pretreated 60 estramustine 60 chronic lymphocytic leukemia CLL 60 mitoxantrone plus 60 canakinumab 60 HBeAg positive 60 Annamycin 59 adalimumab Humira 59 systemic anaplastic large 59 refractory myeloma 59 CIMZIA TM 59 azacitidine 59 recurrent NSCLC 59 AML acute myeloid 59 non hodgkin lymphoma 59 metastatic renal cell carcinoma 59 advanced epithelial ovarian 59 lymphocytic leukemia 59 metastatic renal cell 59 HER2 positive metastatic breast 59 Alemtuzumab 59 Philadelphia Chromosome Positive 59 sunitinib Sutent ® 59 Tarceva erlotinib 59 stage IIIb IV 59 myeloid leukemia 59 ara C 59 post transplant lymphoproliferative 59 castrate resistant 59 juvenile idiopathic arthritis JIA 59 virus HCV protease inhibitor 59 cell acute lymphoblastic 59 cutaneous T 59 Navelbine ® 59 SPRYCEL ® 59 refractory chronic lymphocytic 59 antibody MAb 59 Omacetaxine 59 LHRH receptor positive 59 chlorambucil 59 achieved CCyR 59 lumiliximab 59 TTF Therapy 59 erlotinib Tarceva 59 Lung transplantation 59 epirubicin 59 anthracyclines taxanes 59 baminercept 59 hypomethylating agents 58 recurrent metastatic 58 Fludara 58 Gleevec imatinib mesylate 58 acute myelogenous leukemia AML 58 PKC# 58 Irinotecan 58 TNF inhibitors 58 PREZISTA r 58 CLL SLL 58 lupus nephritis 58 docetaxel Taxotere R 58 Sprycel dasatinib 58 advanced HER2 positive 58 interferon alfa 58 MabThera Rituxan 58 doxorubicin HCl liposome injection 58 metastatic malignant melanoma 58 infusional 5-FU/LV 58 MabCampath 58 standard chemotherapy regimen 58 comparator arm 58 antiretroviral naïve 58 mutated KRAS 58 #mg ATC 58 metastatic RCC 58 fallopian tube carcinoma 58 RRMS patients 58 Epratuzumab 58 advanced metastatic prostate 58 paclitaxel Taxol R 58 basiliximab 58 cell lymphoma CTCL 58 advanced carcinoid 58 taxane refractory 58 mitoxantrone chemotherapy 58 Ph + acute lymphoblastic 58 CYT# potent vascular disrupting 58 receptor tyrosine kinase inhibitor 58 gastrointestinal stromal tumor GIST 58 bendamustine 58 alfa 2a 58 DFMO 58 immunodeficient 58 Hepatocellular Carcinoma HCC 58 hemorrhagic cystitis 58 ACZ# 58 methotrexate therapy 58 dasatinib 58 5FU 58 Ceflatonin 58 cabazitaxel 58 lymphoid malignancies 58 calcineurin inhibitor 58 protease inhibitor PI 57 measurable tumor regressions 57 malignant pleural mesothelioma 57 castration resistant prostate cancer 57 ritonavir boosted 57 VELCADE melphalan 57 heavily pretreated patients 57 leukaemias 57 follicular lymphomas 57 alkylating agents 57 MCyR 57 Peg IFN 57 elevated LDH 57 AGILECT R 57 non metastatic resectable 57 axitinib 57 nonsmall cell lung cancer 57 dasatinib Sprycel 57 trabectedin 57 EGFR TKI 57 Cloretazine 57 gastrointestinal stromal tumors 57 pegylated interferon alpha 57 cediranib 57 idarubicin 57 anthracycline containing 57 Hodgkin lymphoma NHL 57 Gleevec imatinib 57 mcg albinterferon alfa 2b 57 refractory gout 57 unresectable 57 low dose cytarabine 57 FluCAM 57 epithelial ovarian 57 relapsed refractory multiple myeloma 57 diagnosed glioblastoma multiforme 57 plus prednisone prednisolone 57 malignant lymphoma 57 follicular lymphoma FL 57 decompensated liver disease 57 leukemia APL 57 CML CP 57 Waldenstrom macroglobulinemia 57 placebo dexamethasone 57 peginterferon alfa 57 MGd 57 relapsing remitting MS RRMS 57 Gemzar ® 57 metastatic bladder 57 temsirolimus 57 Glioblastoma Multiforme 57 olaparib 57 indolent follicular non 57 oral antidiabetic agents 57 RoACTEMRA 57 Bcr Abl T#I mutation 57 myelodysplastic syndrome MDS 57 cyclophosphamide methotrexate 57 antiretroviral naive 57 alvespimycin 57 complete cytogenetic response 57 imatinib therapy 57 immunocompetent 57 gemcitabine chemotherapy 57 nilotinib Tasigna ® 57 Bortezomib 57 PTLD 57 deep venous thromboses 57 oblimersen 57 haematologic 57 Paxil paroxetine 57 diagnosed multiple myeloma 57 riociguat 57 taxane therapy 57 cisplatin chemotherapy 56 acute leukemias 56 remission induction 56 relapsed acute lymphoblastic 56 ELACYT 56 5-fluorouracil/leucovorin 56 eosinophilic asthma 56 lapatinib Tykerb 56 docetaxel prednisone 56 KRAS mutant tumors 56 Torisel 56 Hodgkin lymphoma HL 56 potentially hepatotoxic 56 refractory NSCLC 56 chronic HCV 56 disease modifying antirheumatic 56 interferon ribavirin 56 Bezielle 56 NMIBC 56 visilizumab 56 ribavirin therapy 56 antiangiogenic therapy 56 papillary renal cell carcinoma 56 leukopenia 56 Cimzia TM 56 gemcitabine carboplatin 56 fludarabine 56 ribavirin RBV 56 LV dysfunction 56 systemic ALCL 56 pamidronate 56 stage IIIB IV 56 HBeAg negative patients 56 peginterferon alpha 2a 56 methotrexate MTX 56 CHOP chemotherapy 56 relapsed multiple myeloma 56 anagrelide 56 sorafenib 56 cetuximab Erbitux ® 56 superficial bladder cancer 56 childhood acute lymphoblastic 56 FOLFIRI 56 Myelodysplastic Syndrome 56 diagnosed Ph + 56 primary hypercholesterolemia 56 weekly subcutaneous injections 56 elevated serum creatinine 56 decitabine 56 ADPKD 56 Acute Myelogenous Leukemia AML 56 mepolizumab 56 HCV RESPOND 2 56 corticosteroid therapy 56 uric acid lowering 56 Relapsed Refractory 56 Amrubicin 56 Aptivus ® 56 advanced medullary thyroid 56 acute lymphoblastic 56 anaplastic astrocytoma 56 #mg BID [001] 56 recurrent glioblastoma 56 APTIVUS r 56 Pegasys ® 56 Gleevac 56 interstitial pneumonitis 56 T#I mutation 56 liver scarring 56 pheochromocytoma 56 FOLFOX chemotherapy 56 anakinra 56 hepatocellular carcinomas 56 lopinavir r 56 chemotherapy cisplatin 56 Chronic Myelogenous Leukemia CML 56 nonmetastatic 56 cytarabine daunorubicin 56 CTEPH 56 hypophosphatemia 56 cell lymphoma ALCL 56 VIDAZA 56 nilotinib 56 5-FU/LV 56 hypercalcemia 56 Tamibarotene 55 myeloablative 55 relapsed acute myelogenous 55 metastatic ovarian cancer 55 panobinostat 55 sorafenib Nexavar ® 55 localized renal 55 deletion 5q 55 YONDELIS 55 hematologic toxicity 55 autoantibody positive 55 cyclophosphamide chemotherapy 55 administered subcutaneously 55 Revlimid lenalidomide 55 Mylotarg 55 lung fibrosis 55 imatinib resistant 55 mapatumumab 55 follicular Non Hodgkin 55 refractory chronic myeloid 55 steroid refractory ulcerative 55 smoldering myeloma 55 Herceptin trastuzumab 55 forodesine 55 phase IIb study 55 resistant hormone refractory 55 ErbB2 positive 55 irinotecan chemotherapy 55 KRAS wild 55 Myelodysplasia 55 sunitinib 55 Seliciclib 55 gastrointestinal stromal tumors GIST 55 refractory Hodgkin 55 alemtuzumab treated 55 immune thrombocytopenic purpura ITP 55 phase IIb trial 55 Jevtana 55 sunitinib malate 55 ELOXATIN 55 Chronic Myeloid Leukemia 55 alefacept 55 PegIFN RBV 55 imatinib mesylate 55 Hashimoto thyroiditis 55 Clofarabine 55 OHR/AVR# 55 refractory indolent non 55 achieved sustained virologic 55 resectable 55 Refractory Hodgkin Lymphoma 55 Cutaneous T 55 abiraterone acetate 55 idiopathic thrombocytopenic purpura 55 drug DMARD 55 BRIM3 55 thymoma 55 refractory multiple myeloma 55 elacytarabine 55 gemcitabine Gemzar ® 55 myelodysplastic syndromes MDS 55 multiple myeloma MM 55 pegylated interferon alfa 2a 55 lung metastases 55 diagnosed chronic myeloid 55 galiximab 55 mutant KRAS 55 vandetanib 55 Sutent sunitinib 55 preoperative chemotherapy 55 advanced metastatic renal 55 diagnosed GBM 55 underwent surgical resection 55 symptomatic BPH 55 KRAS mutations occur 55 bosentan 55 Traficet EN 55 immunomodulatory therapy 55 B CLL 55 iniparib 55 gastrointestinal perforation 55 taxane chemotherapy administered 55 cutaneous T cell 55 plasma uric acid 55 Folfox 55 Femara letrozole 55 plus dexamethasone 55 completely resected 55 mycosis fungoides 55 interferon alfa 2a 55 unresectable stage 55 bronchogenic carcinoma 55 mCRC patients 55 renal insufficiency 55 blastic phase 55 pomalidomide 55 nonalcoholic steatohepatitis NASH 55 elevated ALT 55 fluorouracil 55 exemestane 54 Acute Myeloid Leukemia 54 immune thrombocytopenic purpura 54 PAOD 54 refractory CTCL 54 ACTEMRA TM 54 locoregional recurrence 54 clodronate 54 cirrhosis liver failure 54 doxorubicin cyclophosphamide 54 gastrointestinal stromal tumor 54 pertuzumab 54 chronic myeloid 54 lamivudine refractory patients 54 Cytoxan 54 lymphoblastic leukemia 54 Hurthle cell 54 prostate cancer HRPC 54 nutlin 3a 54 mitoxantrone 54 FOLFOX6 54 phase IIb clinical 54 goserelin 54 situ LCIS 54 T1c 54 nephrosis 54 Acute Bacterial Sinusitis ABS 54 transcriptase inhibitor NNRTI 54 gefitinib 54 follicular NHL 54 medically inoperable 54 relapsed ovarian cancer 54 PegIntron 54 gemcitabine cisplatin 54 Mitoxantrone 54 MAGE A3 ASCI 54 ZOLINZA 54 intravenous belinostat 54 DLBCL 54 seropositive patients 54 rufinamide 54 liver decompensation 54 acute promyelocytic leukemia 54 dexamethasone Decadron 54 pT2 54 anti leukemic 54 ductal breast cancer 54 huN# DM1 54 lymphoma CTCL 54 candidemia 54 dacarbazine 54 diabetic kidney 54 telaprevir dosed 54 Acute Myelogenous Leukemia 54 TACE 54 malignant neoplasm 54 rimonabant #mg 54 myeloproliferative disorder 54 histologically confirmed 54 basal cell nevus syndrome 54 rindopepimut 54 chronic hepatitis cirrhosis 54 SHPT 54 differentiated thyroid 54 recurrent genital herpes 54 progressive PsA 54 acute myeloid 54 relapsed Acute Myeloid 54 amrubicin 54 CTAP# 54 splenectomized patients 54 Vidaza azacitidine 54 subcutaneous enoxaparin 54 imatinib mesylate Gleevec 54 biochemical relapse 54 PEGINTRON TM 54 venlafaxine XR 54 decompensated cirrhosis 54 inoperable pancreatic cancer 54 Acute Myeloid Leukaemia AML 54 plus gemcitabine 54 macroglobulinemia 54 desvenlafaxine succinate 54 panitumumab Vectibix 54 postoperative chemotherapy 54 leukemia CML 54 Zytiga 54 chronic myeloid leukemia CML 54 autologous transplants 54 tocilizumab 54 glioblastoma multiforme GBM 54 lung metastasis 54 metastatic CRPC 54 JMML 54 pancreatic adenocarcinoma 54 glufosfamide 54 cell carcinoma RCC 54 curative resection 54 oral vancomycin 54 Omnitarg 54 FOLFOX4 54 cholinesterase inhibitor 54 CD# mAb 54 IV metastatic melanoma 54 cell chronic lymphocytic 54 bevacizumab Avastin ® 54 pT3 54 lymphocytosis 54 colorectal cancer liver metastases 54 antithymocyte globulin 54 adverse cytogenetics 54 standard chemotherapy regimens 54 chemotherapeutic regimens 54 IV NSCLC 54 PNP inhibitor 54 raltegravir 54 abiraterone 54 neurologic progression 54 interferon alfa 2b 54 bladder carcinoma 54 octreotide 54 myelofibrosis MF 54 fallopian tube cancers 54 ethambutol 53 rituximab refractory 53 bone marrow suppression 53 squamous cell carcinoma SCC 53 Retreatment 53 Stage IIIB IV 53 plus prednisone 53 pancreatic carcinoma 53 GISTs 53 Metastatic breast cancer 53 receiving golimumab 53 non myeloid malignancies 53 idiopathic PAH 53 risperidone Risperdal 53 DMARDs 53 Pemetrexed 53 LEXIVA r 53 cytogenetic responses 53 hepatocellular carcinoma HCC 53 peritoneal carcinomatosis 53 CCyR 53 mycophenolate mofetil 53 prior chemotherapy regimens 53 precancerous condition 53 metastatic GIST 53 risperidone olanzapine 53 biliary tract cancer 53 relapsed refractory 53 colorectal liver metastases 53 sarcomatoid 53 HCV genotype 1 53 thrombocytopenia neutropenia 53 Etanercept 53 DMARD therapy 53 peginterferon alfa 2b 53 prostate cancer CRPC 53 myelodysplasia 53 oral clodronate 53 Pharmacokinetics PK 53 anti TNF 53 Wegener granulomatosis 53 complement inhibitor eculizumab 53 papillary carcinoma 53 tyrosine kinase inhibitors 53 irinotecan containing 53 GnRH agonist 53 HGS# 53 Infusion Reactions Severe 53 relapsed CLL 53 hepatic metastases 53 Advagraf 53 TMP SMX 53 elevated lipase 53 cytotoxic therapy 53 HGS ETR1 53 cryptococcal meningitis 53 plus methotrexate 53 olmesartan 53 Zollinger Ellison syndrome 53 anti angiogenic therapy 53 metastatic SCCHN 53 velafermin 53 8mg/kg 53 VFEND 53 romiplostim 53 mg kg dose 53 eribulin 53 iclaprim 53 basal cell carcinoma BCC 53 arsenic trioxide 53 HCV infected 53 boosted protease inhibitor 53 ovarian carcinoma 53 etoposide 53 achieved sustained virological 53 beta interferon 53 metastatic renal 53 vismodegib 53 proliferative diabetic retinopathy 53 mycophenolate 53 polyp recurrence 53 TMC# C# 53 onset diabetes mellitus 53 recurrent GBM 53 refractory cutaneous T 53 regorafenib 53 ER CHOP 53 5 fluorouracil 53 neoadjuvant therapy 53 chronic immune thrombocytopenic 53 cilengitide 53 chronic HCV genotype 53 lymphopenia 53 liver histology 53 CANCIDAS 53 headache abdominal pain 53 opioid induced constipation OIC 53 nephritis 53 keloid scarring 53 castrate resistant prostate cancer 53 grade gliomas 53 neutropenic 53 allogeneic stem cell 53 indolent NHL 53 HBeAg seroconversion 53 relapsing remitting multiple sclerosis 53 ischemic colitis 53 refractory CLL 53 Cloretazine ® 53 Toxicities 53 thrombocytopenic patients 53 stage IIIb 53 steroid prednisone 53 alanine aminotransferase ALT 53 nephrotic syndrome 53 virological failure 53 QD dosing 53 IRESSA 53 Diffuse Large B 53 intravenous cyclophosphamide 53 SCCHN 53 CRVO 53 Myelofibrosis 53 de novo kidney transplant 53 cytoreduction 52 virologic response 52 motesanib 52 Onrigin 52 achieve sustained virologic 52 Natalizumab 52 relapsed myeloma 52 6 mercaptopurine 52 prostate adenocarcinoma 52 Marfan mice 52 hepatic failure 52 pilocytic astrocytoma 52 chronic thromboembolic pulmonary 52 detectable HCV RNA 52 B Cell Lymphoma 52 ixabepilone 52 EGFR mutation positive 52 anaplastic 52 SJIA 52 relapsers 52 abatacept Orencia 52 LHRH analogues 52 aHUS 52 divalproex sodium 52 CAELYX 52 maximally tolerated lipid lowering 52 TREANDA 52 FOLFIRI alone 52 imatinib 52 Telcyta 52 endoscopic remission 52 malignant fibrous histiocytoma 52 adjuvant radiotherapy 52 previously untreated follicular 52 underwent resection 52 refractory ovarian cancer 52 % CI #.#-#.# [007] 52 primary immunodeficiency PI 52 macroalbuminuria 52 pegfilgrastim 52 virological response 52 Adjuvant chemotherapy 52 Mantle Cell Lymphoma 52 myelogenous leukemia 52 refractory lymphoma 52 advanced NSCLC 52 rALLy 52 thyrotoxicosis 52 receiving VICTRELIS 52 dose dexamethasone 52 lenalidomide 52 active comparator 52 HCV SPRINT 52 metastatic NSCLC 52 tofacitinib 52 ankylosing spondylitis AS 52 tamoxifen therapy 52 Acute Myeloid Leukemia AML 52 acute myelogenous 52 HAART regimen 52 glioblastoma brain tumor 52 grade glioma 52 Kantarjian 52 peg interferon 52 Phase IIb trials 52 angiosarcoma 52 EGFR expressing 52 hyperammonemia 52 Gorlin syndrome 52 oral rivaroxaban 52 atypical neuroleptics 52 Relapsing remitting MS 52 relapsing remitting 52 zoledronic acid 52 placebo controlled clinical trials 52 temozolomide 52 null responders 52 bortezomib 52 cardiac amyloidosis 52 rituximab 52 congenital ichthyosis 52 hyperparathyroidism 52 OADs 52 Lupus nephritis 52 neurological manifestations 52 pretransplant 52 relapsed AML 52 complete remissions 52 severe exacerbations 52 pediatric malignancies 52 Decitabine 52 bevacizumab Avastin 52 receiving highly emetogenic 52 Taxotere ® 52 adjunctive placebo 52 cis retinoic acid 52 efficacy endpoint 52 Pegasys plus Copegus 52 durable remissions 52 underwent liver transplantation 52 familial ALS 52 TNF inhibitor 52 oral ridaforolimus 51 histologies 51 dirucotide 51 hyperlipemia 51 unresectable recurrent 51 peginterferon 51 rhabdoid 51 myelodysplastic syndromes 51 paclitaxel carboplatin 51 relapsed SCLC 51 acute GvHD 51 neutrophil counts 51 infliximab therapy 51 seminoma 51 recurrent malignant glioma 51 chronic GVHD 51 virologic failure 51 Rituximab 51 patients evaluable 51 debilitating complication 51 Clolar 51 MLL AF9 51 sulfasalazine 51 rapid virologic response 51 immune reconstitution 51 Acute Myeloid Leukaemia 51 leucopenia 51 oxaliplatin 51 juvenile myelomonocytic leukemia 51 carboplatin paclitaxel 51 EXJADE 51 virologically 51 PASI scores 51 carcinoid 51 HCV infection 51 Acute lymphocytic leukemia 51 #mg/m# [001] 51 partial remissions 51 progression TTP 51 CVP cyclophosphamide vincristine 51 lintuzumab 51 lupus scleroderma 51 refractory CML 51 immunosuppressed 51 Eisenmenger syndrome 51 adjuvant tamoxifen 51 thymic carcinoma 51 liver metastases 51 Tardive dyskinesia 51 FOLFOX 51 acute mania 51 complete cytogenetic 51 unresectable locally advanced 51 pegylated interferon peg IFN 51 bortezomib refractory 51 #mg/day [002] 51 efavirenz EFV 51 essential thrombocythemia 51 hormone refractory 51 Follicular lymphoma 51 biologic therapy 51 Follicular Lymphoma 51 pancreatic NET 51 PLX STROKE targeting 51 abatacept 51 chemoradiotherapy 51 esophageal perforation 51 polycystic kidneys 51 interstitial nephritis 51 leukemic 51 pegylated interferon alfa 51 Dacogen injection 51 peginterferon alfa 2a 51 lymphoblastic lymphoma 51 cetuximab 51 anthracycline therapy 51 Chronic pancreatitis 51 AAT deficiency 51 darunavir ritonavir 51 ANCA associated 51 phase Ib 51 neoadjuvant chemotherapy 51 REVLIMID lenalidomide 51 afatinib 51 clofarabine 51 dosed orally 51 IV melanoma 51 Newly Diagnosed Multiple Myeloma 51 neutropenic patients 51 anthracycline 51 peritoneal cancer 51 MDS AML 51 anti TNF alpha 51 DOXIL ® 51 visceral metastases 51 undetectable HBV DNA 51 EGFR expressing mCRC 51 p#HER# positive 51 drugs DMARDs 51 dosing cohort 51 liver metastasis 51 dose melphalan 51 vinflunine 51 erythropoietic 51 HER2 negative 51 thrombocytosis 51 refractory HL 51 prospectively defined 51 median PFS 51 ACR# responses 51 Cell Lymphoma CTCL 51 febrile neutropenia 51 late onset Pompe 51 arbaclofen 51 CR nPR 51 CIN3 51 etanercept 51 metastatic prostate cancer 51 variceal hemorrhage 51 duodenal ulcer 51 severe malignant osteopetrosis 51 infliximab 51 RG# [001] 51 naïve HCV 51 unfavorable cytogenetics 51 erlotinib 51 sustained virologic response 51 refractory metastatic 51 carcinoma mCRC 51 operable breast cancer 50 PXD# 50 COPAXONE ® 50 Myocardial infarction 50 metastatic CRC 50 mycophenolate mofetil MMF 50 FOLPI regimen 50 Relapsed 50 antiestrogen therapy 50 generalized tonic clonic seizures 50 neutropenic fever 50 4mg/kg 50 Pulmonary hypertension 50 NNRTI 50 cardiovascular cerebrovascular 50 cystic fibrosis chronic pancreatitis 50 atrophic gastritis 50 Median PFS 50 hormone refractory prostate cancer 50 ulcerative colitis UC 50 Asymptomatic 50 L dopa 50 achieved PASI 50 teratogenic effects 50 tumor regressions 50 induce remission 50 ALT flares 50 relapsing multiple sclerosis 50 chronic idiopathic 50 vinorelbine 50 Rituxan 50 venlafaxine ER 50 refractory systemic anaplastic 50 HERCEPTIN 50 lobular carcinoma 50 nitazoxanide 50 occlusive disease 50 evaluable subjects 50 anaplastic astrocytoma AA 50 papillary thyroid carcinoma 50 FOLPI 50 radioiodine therapy 50 cytarabine 50 topotecan 50 pseudomembranous colitis 50 lichen planus 50 urothelial cancer 50 transaminase elevations 50 moderate renal impairment 50 systemic mastocytosis 50 tumor regression 50 relapsed GBM 50 androgen ablation 50 CPOP R 50 taxane 50 colorectal neoplasms 50 class mGluR5 inhibitor 50 CRu 50 clinically detectable 50 remitting MS 50 metastatic HRPC 50 experienced virologic failure 50 recurrent VTE 50 undergone hysterectomy 50 refractory acute promyelocytic 50 T Cell Lymphoma 50 invasive fungal infection 50 gestational hypertension 50 tumor shrinkage 50 torsade de pointes 50 breast carcinoma 50 metastatic squamous cell carcinoma 50 familial adenomatous polyposis 50 acute gout flares 50 intermittent dosing 50 ALND 50 Ribavirin 50 recurrent ovarian cancer 50 Glioblastoma Multiforme GBM 50 leukoencephalopathy 50 cryptogenic cirrhosis 50 gemcitabine 50 myelofibrosis 50 metastatic bone 50 imetelstat 50 surrogate endpoint 50 Median survival 50 neuroleptics 50 dose cohorts 50 hepatitis C genotype 50 voreloxin 50 cirrhotic 50 Wilms tumors 50 chemoradiation therapy 50 IV malignant melanoma 50 alveolar rhabdomyosarcoma 50 chemotherapies